Back to top
more

Artivion (AORT)

(Delayed Data from NYSE)

$26.60 USD

26.60
297,146

+0.60 (2.31%)

Updated Jul 11, 2024 04:00 PM ET

After-Market: $26.63 +0.03 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (153 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Artivion (AORT) Q4 Earnings Surpass Estimates

Artivion (AORT) delivered earnings and revenue surprises of 158.82% and 1.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Artivion (AORT) Upgraded to Buy: What Does It Mean for the Stock?

Artivion (AORT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts Think Artivion (AORT) Could Surge 79%: Read This Before Placing a Bet

The consensus price target hints at a 79.4% upside potential for Artivion (AORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 173% Upside in Artivion (AORT): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 173.4% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Artivion (AORT) Reports Q3 Loss, Tops Revenue Estimates

Artivion (AORT) delivered earnings and revenue surprises of 54.55% and 0.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates

ViewRay (VRAY) delivered earnings and revenue surprises of 0% and 4.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

SARTORIUS (SARTF) Q3 Earnings and Revenues Top Estimates

SARTORIUS (SARTF) delivered earnings and revenue surprises of 7.39% and 7.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

KORU Medical Systems Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 0% and 4.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

What Makes Artivion (AORT) a New Buy Stock

Artivion (AORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Artivion (AORT) Soars 10.2%: Is Further Upside Left in the Stock?

Artivion (AORT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Sensus Healthcare, Inc. (SRTS) Moves 7.3% Higher: Will This Strength Last?

Sensus Healthcare, Inc. (SRTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Strength Seen in Masimo (MASI): Can Its 7.7% Jump Turn into More Strength?

Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Artivion (AORT) Reports Break-Even Earnings for Q4

Artivion (AORT) delivered earnings and revenue surprises of 100% and 1.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Artivion (AORT) Q4 Earnings Expected to Decline

Artivion (AORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.